

## Censorship masquerading as "transparency": the EMEA assessment report on rimonabant

We often ask the European Medicines Agency (EMEA) for information that is not available on the agency's website. Their response in the case of rimonabant, a drug that has now been withdrawn from the market, is an example of how drug regulatory agencies practice censorship.

The EMEA provided us with several documents, including a report from the Swedish agency (Läkemedelsverket "Acomplia Final Assessment Report"). Yet, only 3 of the 68 pages in this report were legible: the rest of the text has been systematically blacked out, line by line, even including the date of the report.

**©Prescrire** 


Prescr Int 2009; 18 (103): 231.



## Acomplia/Zimulti


EU/1/06/344/001-009

Final Assessment Report



















ı ı I

Date:

















	. * 			*	
<del></del>				<u></u>	
				,	
		· ·		<u> </u>	
	· <b>I</b>			· <b>I</b>	
	<u> </u>		1		
	<u> </u>		·	·	<u> </u>
	<u>_</u>	· · · · · · · · · · · · · · · · · · ·			
	<b>—</b>	<u> </u>		<u> </u>	
			×		<u> </u>
	1		· · ·		-
	I				-
		<u> </u>			
				- <del>-</del>	<u> </u>
	<u> </u>			<u>-</u>	<u> </u>
	<del></del>		. 1		
		<b>I</b>	3		
	]				
	1				■
	-				
	i i			*	
				-	🛮
	I			. 1	
				. 1	
		· ···		I	
		<u> </u>			
		<u> </u>			
		<u> </u>			
					<u>.</u>
	: <u> </u>				<u> </u>
	. <b>J</b>		· · · · · · · · · · · · · · · · · · ·	• .	
	<u> </u>		· · · · ·		I



Date: I 1 F i Ï ı












			-
I I	I		
			1
			1
	1		<u> </u>
· <b>I</b>	:		
	<b>I</b> .		
· : I			
		1	
	1 1	-	1
<u>I</u>	· ·		I
			I
	•		
-			<u> </u>



			I I
_	ı		Ī
	-		1
1			
1			
			· •
		· ·	
	· · · · · · · · · · · · · · · · · · ·		1 1
	-		
			l I



-		
-	<b>_</b>	
	1	
	<u> </u>	
-	ı	
	<u> </u>	
•		,









			Date.					
						•		
			• •					
		·.						
	 	•			•			
								• •
	•							
·			t in the					
		*						
							,	
				. /				
				•				
		·				· ·		
			The second	-		 · · · · · · · ·		





Date: I I 23 (68)




















		Date:	·		
				.   <del></del>	<del></del>
				· .	<u></u>
z.					
		 I			
				<b>_</b>	
				<u>I</u>	
				<u>.                                    </u>	
		·			
		·			· · · · · ·
			- :		· ·
			1		
		· · · · · · · · · · · · · · · · · · ·	•	_	•
				<b>■</b>	
				<u> </u>	
				<b>I</b>	
	· .				
·					
			* •		30 (68)















LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY Date:







Date:		
	÷	

Downloaded from english.prescrire.org on 08/12/2025 Copyright(c)Prescrire. For personal use only.



		Į.	Date:					
			٠			•		
	•							
					•			
	ı .	٠.	,					
				'	*.		·	
				•		•		
			٠					
								ŀ













Risk Management Plan The fourth version of the European RMP of rimonabant, is submitted as initially planned Compared to the previous European RMP (third version), dated 18-Aug-2007, the major changes regarding the content are as follows: The list of identified and potential risks has been updated with the addition of the identified risk of psychotic disorders. Otherwise, data about the already listed risks in the safety specifications have been updated with: - integration of a newly completed study ( ) in the pool of completed phase III clinical studies in the obesity / type 2 diabetes program. - review of serious adverse events from 4 phase I and 16 phase III and IV studies that are ongoing during the period covered by PSUR 3. presenting background incidence rates of epidemiology results depression, suicide death and suicide attempts, anxiety, seizures and cardiovascular events in an obese American population. Results from depression among smokers in the cohort are also provided, as planned in the initial European RMP, although smoking cessation is not an indication for rimonabant. results from new waves of prescription surveys done in 3 European countries ( ) after the changes in the SPC in July 2007 reinforcing the contraindication and cautions in depressed patients, as well as results describing the use of rimonabant in longitudinal medical record databases: • The Pharmacovigilance Plan has been updated as follows: - update in the program of life cycle management studies, - submission of the protocol of the study assessing the background rates of suicidal events database. submission of the protocol for assessing the association between nonrecurrent suicide attempts and the use of rimonabant and A new pharmacoepidemiological study • The risk minimization plan has been updated regarding both the description of the educational program and the tools to measure the effectiveness of minimization, as follows: - the description of the communication process through which the MAH conveys the appropriate labeling information to the prescribers has been specified, focusing on actions that are different from promotional activities. - re-submission of the prescription survey protocol as originally provided in the first European RMP, updated with a new questionnaire for prescription surveys taking into

Date:

protocol for "rimonabant in Clinical Practice", a drug utilization survey in primary care

account the changes in labeling of July 2007.

– submission of an outline for a prescription study



ra case-control study to assess the risk of suicide attempts (SA) in association with the use frimonabant by using the information system, i.e. definition and enrollment of cases and controls, exposure and risk factor ascertainment, data validation and power estimation verall, the system seems to provide valuable resources to perform the study and to emerate meaningful results. Also, the case-control methodology, in the briefly described spects, appears adequate for the purpose of the study, yielding an 80 % power to detect a 2 3-fold increase of the risk for SA in users of rimonabant, given two different assumptions in the prevalence of rimonabant use in referents. There are many challenges foreseen in the order of the study, important ones being characterization of the psychiatric disorder in SA intensity and possible risk factors that could predispose exposed obese attents for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be uportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full analytical protocol for the study is awaited.	ssessor's comme	<i></i>					
or a case-control study to assess the risk of suicide attempts (SA) in association with the use of rimonabant by using the information system, i.e. definition and enrollment of cases and controls, exposure and risk factor ascertainment, data validation and power estimation, exerall, the system seems to provide valuable resources to perform the study and to expect meaningful results. Also, the case-control methodology, in the briefly described expects, appears adequate for the purpose of the study, yielding an 80 % power to detect a 2 standard increase of the risk for SA in users of rimonabant, given two different assumptions in the prevalence of rimonabant use in referents. There are many challenges foreseen in the conduct of the study, important ones being characterization of the psychiatric disorder in SA attents taking rimonabant and possible risk factors that could predispose exposed obese attents for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, estailed information on the the index psychiatric events and on relevant comorbidity will be apportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and	egarding the syn	eopsis	. <i>Ti</i>	he synops	is describes	the various app	roaches
and controls, exposure and risk factor ascertainment, data validation and power estimation, everall, the system seems to provide valuable resources to perform the study and to expects, appears adequate for the purpose of the study, yielding an 80 % power to detect a 25 3-fold increase of the risk for SA in users of rimonabant, given two different assumptions in the prevalence of rimonabant use in referents. There are many challenges foreseen in the product of the study, important ones being characterization of the psychiatric disorder in SA attents taking rimonabant and possible risk factors that could predispose exposed obese attents for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be aportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and			e risk of sui	cide atten	npts (SA) in	association with	h the use
enerate meaningful results. Also, the case-control methodology, in the briefly described expects, appears adequate for the purpose of the study, yielding an 80 % power to detect a 25 3-fold increase of the risk for SA in users of rimonabant, given two different assumptions in the prevalence of rimonabant use in referents. There are many challenges foreseen in the product of the study, important ones being characterization of the psychiatric disorder in SA attents taking rimonabant and possible risk factors that could predispose exposed obese attents for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be apportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and		using the in	formation s	ystem, i.e	. definition d	and enrollment	of cases
enerate meaningful results. Also, the case-control methodology, in the briefly described spects, appears adequate for the purpose of the study, yielding an 80 % power to detect a 25 3-fold increase of the risk for SA in users of rimonabant, given two different assumptions in the prevalence of rimonabant use in referents. There are many challenges foreseen in the onduct of the study, important ones being characterization of the psychiatric disorder in SA attents taking rimonabant and possible risk factors that could predispose exposed obese attents for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be apportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and							
spects, appears adequate for the purpose of the study, yielding an 80 % power to detect a 2 3-fold increase of the risk for SA in users of rimonabant, given two different assumptions in the prevalence of rimonabant use in referents. There are many challenges foreseen in the orduct of the study, important ones being characterization of the psychiatric disorder in SA attents taking rimonabant and possible risk factors that could predispose exposed obese attents for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be apportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and	everali, ine	system seems to p	be egge een	iable reso tual math	nirces to per	form the study	and to
s 3-fold increase of the risk for SA in users of rimonabant, given two different assumptions in the prevalence of rimonabant use in referents. There are many challenges foreseen in the onduct of the study, important ones being characterization of the psychiatric disorder in SA attents taking rimonabant and possible risk factors that could predispose exposed obese attents for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be aportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and	spects, appears a	idequate for the m	urpose of th	e study v	ielding an 8	ine vriejty descr 0 % nower to di	iveu etect a 2
In the prevalence of rimonabant use in referents. There are many challenges foreseen in the product of the study, important ones being characterization of the psychiatric disorder in SA attients taking rimonabant and possible risk factors that could predispose exposed obese attents for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be apportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and	3-fold increase	of the risk for SA	in users of r	imonaba	nt, given two	o different assum	nptions
atients taking rimonabant and possible risk factors that could predispose exposed obese atients for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be aportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and	n the prevalence	of rimonabant use	e in referent	s. There o	are many ch	allenges foresee	n in the
atients for SA. One crucial issue will be to address whether there is an independent effect of monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be aportant.  In summary, the study as described in the synopsis is broadly endorsed. However, a full and	onduct of the stud	dy, important ones	being char	acterizati	on of the ps	ychiatric disora	ler in SA
monabant froms the effect of weight reduction per se in these obese patients. Therefore, etailed information on the the index psychiatric events and on relevant comorbidity will be aportant. In summary, the study as described in the synopsis is broadly endorsed. However, a full and	atients taking rim	10nabant and poss	sible risk fac	ctors that	could predi	spose exposed c	bese
etailed information on the the index psychiatric events and on relevant comorbidity will be aportant. In summary, the study as described in the synopsis is broadly endorsed. However, a full and	atients for SA. Oi	ne crucial issue wi	ill be to ada	tress whet	her there is	an independent	effect o
aportant. In summary, the study as described in the synopsis is broadly endorsed. However, a full and							
n summary, the study as described in the synopsis is broadly endorsed. However, a full and	eiaitea injormatio mortant	on on the the thae.	x psychiairi	c evenis t	ina on reiev	ani comorbiaity	will be
etailed protocol for the study is awaited.		studv as described	in the synor	psis is bro	adlv endors	sed. However a	full and
	etailed protocol f	for the study is aw	aited.		cicity cricion	occi. However, a	jun ana
	λ						
					٠.		•
					100		
			•				
			r e		7 5 5 		
					ν		· ·
					×		
					·		





Date: Regarding the RMP The results from the Drug Utilization Study should be provided as soon as possible. Timelines for the study Rimonabant In Clinical Practice should be provided by the company. This study could provide valuable data, provided there will be a sufficient size of study population. The Information System study as described in the synopsis is broadly endorsed. However, a full and detailed protocol for the study is awaited. The protocol-or synopsis for the new pharmacoepidemology study should be provided by the company.





-			Date:				
				•	٠		- ,
						-	
							•
				•			
•	. :		,			•	
					-	, ,,,,,	
			**				
					•		
		 			· .	The second second	









Date:		
	:	
·		
		e .




















		Date:									
					÷						
											•
										<b></b> .	
					•						
			e de la companya de l					•			
:											
		 ,									_
									• .		
	 			N N	. •					· .	
			,								
								-			
					٠.		- '		-44		
		•									
				•		•					
		•	,			-					
						٠					
								÷			
										•	
			•								
											ŀ
				٠							
			*								
			*					٠		61 (68	;)







63.(68)













